---
title: "KalVista Pharmaceuticals, Inc. (KALV.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KALV.US.md"
symbol: "KALV.US"
name: "KalVista Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T03:07:01.482Z"
locales:
  - [en](https://longbridge.com/en/quote/KALV.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KALV.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KALV.US.md)
---

# KalVista Pharmaceuticals, Inc. (KALV.US)

## Company Overview

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.kalvista.com](https://www.kalvista.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: D (0.78)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 4.11% |  |
| P/B Ratio | -72.50 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1424726162.88 |  |
| Revenue | 114480000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -190.18% | E |
| Profit Margin | -14242.43% | E |
| Gross Margin | -1004.63% | E |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | -43.26% | D |
| Total Assets YoY | 7.65% | B |
| Net Assets YoY | -76.39% | E |
| Cash Flow Margin | 82.32% | C |
| OCF YoY | 0.00% | D |
| Turnover | 0.01 | E |
| Gearing Ratio | 81.07% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - KalVista Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "4.11%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-72.50",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1424726162.88",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "114480000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-190.18%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-14242.43%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-1004.63%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-43.26%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.65%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-76.39%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "82.32%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "81.07%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.48 | 459/386 | - | - | - |
| PB | -72.52 | 544/386 | 20.94 | 16.13 | 6.76 |
| PS (TTM) | 12.45 | 178/386 | 580.25 | 526.73 | 389.73 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 14% |
| Hold | 6 | 86% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 26.77 |
| Highest Target | 42.00 |
| Lowest Target | 27.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KALV.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KALV.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KALV.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KALV.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**